|
Jul 17
|
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
|
|
Jul 4
|
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
|
|
Jun 20
|
Prothena to lay off majority of staff; Zealand shares obesity drug data
|
|
Jun 18
|
Prothena Announces Corporate Restructuring
|
|
May 28
|
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform
|
|
May 27
|
Update: Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued
|
|
May 27
|
Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results
|
|
May 27
|
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
|
|
May 27
|
Biogen strikes RNAi deal with City; Aurion withdraws IPO
|
|
May 27
|
Why Is Prothena Stock Trading Lower On Tuesday?
|
|
May 26
|
Prothena’s Phase III trial for AL amyloidosis treatment misses endpoint
|
|
May 23
|
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
|
|
Feb 22
|
Prothena Full Year 2024 Earnings: Misses Expectations
|
|
Feb 21
|
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
|
|
Feb 21
|
Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ...
|
|
Feb 20
|
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 20
|
Prothena: Q4 Earnings Snapshot
|
|
Feb 20
|
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
|
|
Feb 13
|
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
|
|
Dec 30
|
Prothena Announces Board of Directors Update
|